-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASTCTChat Q1: How do the findings of this paper impact your survivorship plan? https://t.co/kgBOAbvN4P https://t.co/yloZjbWW5W
-
-
Mashup Score: 3Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Use of human leukocyte antigen (HLA)-mismatched donors could enable more patients with ethnically diverse backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United States. However, real-world trends and outcomes following mismatched donor HCT for diverse patients remain largely undefined.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Evaluation of Children with Malignancies for Blood and Marrow Transplantation: A Report from the ASTCT Committee on Practice Guidelines - 1 year(s) ago
Evaluation of a candidate for hematopoietic cell transplantation (HCT) is a complex process with substantial intercenter variability. Although literature providing guidance for evaluating the eligibility of adults is well established, similar guidance for children is lacking. To address gaps between adult recommendations and the specific needs of children, we convened a panel of pediatric HCT…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) - 1 year(s) ago
Hemophagocytic lymphohistiocytosis (HLH), as classically defined, is a severe hyperinflammatory syndrome characterized by hyperferritinemia, coagulopathy, hepatic dysfunction and cytopenias amongst a host of other manifestations.1,2 The unifying pathophysiology is hyperinflammation related to unmitigated T cell and macrophage activation, often with concurrent NK-cell dysfunction, which induces a…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1SARS-CoV-2 vaccine immunogenicity among chimeric antigen receptor T-cell therapy recipients - 1 year(s) ago
Chimeric antigen receptor T-cell (CAR T-cell) therapy targeting B-cell maturation antigen (BCMA) and CD19 revolutionized treatment for patients with relapsed/refractory hematologic malignancies. Evolving data demonstrates that patients who receive CD19-directed or BCMA-directed CAR T-cell therapy may be at high risk for severe COVID-19 and unfavorable outcomes such as prolonged or intractable…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma - 1 year(s) ago
Myeloma AHCT survivors in stable remission have no clinically meaningful worsening in physical functioning compared to general population.. Survivorship programs should address ongoing distress due to health burden, uncertainty, and finances in myeloma survivors, along with targeted interventions for modifiable health behaviors such as nutrition and exercise.
Categories: Hem/Oncs, Latest HeadlinesTweet
#ASTCTChat Q4: Does the data presented in the paper give you the inclination to try to implement a different measure? https://t.co/kgBOAbvffh https://t.co/bHpSZaiB6D